netFormulary NHS
Northern Lincolnshire
Formulary
 Search
 Formulary Chapter 10: Musculoskeletal and joint diseases - Full Chapter
10.01.03  Expand sub section  Drugs which suppress the rheumatic disease process
10.01.03  Expand sub section  Gold
10.01.03  Expand sub section  Penicillamine
10.01.03  Expand sub section  Antimalarials
10.01.03  Expand sub section  Drugs affecting the immune response to top
Abatacept (Orencia®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

injection

 
Link  NHS England Clinical Commissioning Statement: Biologics for Juvenile Idiopathic Arthritis
Link  NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Link  NICE TA280: Rheumatoid arthritis - abatacept (2nd line) (rapid review of TA234)
Link  NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Link  NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
 
Adalimumab (Humira®)
(rheumatology)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
CCG
Homecare
 
Link  NHS England Clinical Commissioning Statement: Biologics for Juvenile Idiopathic Arthritis
Link  NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Link  NICE TA199: Psoriatic arthritis
Link  NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Link  NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Link  NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
 
Apremilast ( (Ortezla® ))
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
CCG

Tablet
- approved in line with NICE TA419 and NICE TA433

 
Link  MHRA Safety Update: Apremilast-risk of suicidal thoughts and behaviour
Link  NICE TA433 : Apremilast for treating active psoriatic arthritis
 
Cytotoxic Drug Azathioprine
(rheumatology)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber Shared Care Protocol

tablet

 
Link  Prescribing Framework for Azathioprine in Rheumatic Diseases
 
Certolizumab Pegol (Cimzia®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  MHRA: Tuberculosis risk—screen patients before starting treatment
Link  NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Link  NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Link  NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Link  NICE TA445 : Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARD
Link  NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis
 
Etanercept (Benepali®)
(Biosimilar)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

subcutaneous injection

 
Link  NICE TA35: Adult psoriasis
Link  MHRA: Tuberculosis risk—screen patients before starting treatment
Link  NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor
Link  NICE TA199: Psoriatic arthritis
Link  NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Link  NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
 
Etanercept (Enbrel®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

subcutaneous injection

 
Link  NICE TA35:Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis
Link  MHRA: Tuberculosis risk—screen patients before starting treatment
Link  NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor
Link  NICE TA199: Psoriatic arthritis
Link  NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA
Link  NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Link  NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
 
Golimumab (Simponi®)
(Rheumatology)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA220:Golimumab for the treatment of psoriatic arthritis
Link  NICE TA225:Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
Link  NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
Link  NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Link  NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
 
Infliximab
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
CCG
 
Link  NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor)
Link  NICE TA199: Psoriatic arthritis
Link  NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Link  NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Link  NICE TA497:Golimumab for treating non-radiographic axial spondyloarthritis
 
Leflunomide
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber Shared Care Protocol

Tablet

 
Link   MHRA advice regarding risk of hepatotoxicity, haemotoxicity, infections, and birth defects
Link  Prescribing Framework for Leflunomide in Rheumatic Diseases
 
Cytotoxic Drug Methotrexate
(rheumatology)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber Shared Care Protocol

Tablets

 

 
Link  Prescribing Framework for Methotrexate Tablets in Rheumatic Diseases
 
Methotrexate (Metoject®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

Subcutaneous injecton is currently Hospital Only

 
 
Rituximab (rheumatology) (MabThera®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

infusion

 
Link  NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
 
Sarilumab  ( (Kevzara®) )
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

Injection - prefilled syringe of pen

 
Link  NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
 
Secukinumab
((Cosentyx®))
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

Injection - syringe or pre-filled pen.

 
Link  NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Link  NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
 
Tocilizumab (RoActemra®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

infusion

 
Link  NICE TA 238: Tocilizumab in juvenile idiopathic arthritis
Link  NICE TA247:Tocilizumab in RA
Link  NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Link  NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Link  NICE TA518: Tocilizumab for treating giant cell arteritis
 
Tofacitinib ((Xeljanz®))
(Rhuematology)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
CCG

Tablet

 
Link  NICE TA480:NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
Link  NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Link  NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
 
Ustekinumab
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
CCG

Injection

 
Link  NICE TA340:Ustekinumab for treating active psoriatic arthritis
Link  NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
 
10.01.03  Expand sub section  Cytokine modulators
10.01.03  Expand sub section  Sulfasalazine
 ....
 Non Formulary Items
Anakinra  (Kineret®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

Green -Medicines suitable for routine use within primary care and Secondary care Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies  

Amber

Amber- Medicines suitable to be prescribed in primary care after specialist /Consultant recommendation or initiation. A supporting prescribing guideline may be requested which must have been agreed by the relevant secondary care trust Medicines and Therapeutic Committee and approved by the Area Prescribing Committee.   

Red

Red-Hospital initiation and continuation only  

Amber Shared Care Protocol

AMBER SHARE CARE PROTOCOL- Medicines that should be initiated by a specialist and prescribed by primary care prescribers only under a shared care protocol, once the patient has been stabilised  

Blue

To be supplied from the appropriate commissioned provider.   

Green 2

GREEN 2- to be prescribed by primary care only   

Grey

GREY- NON FORMULARY (As agreed by Area Prescribing Committee)  

netFormulary